Patent ID: 11926667
Assignee: JANSSEN BIOTECH, INC.
Field: Biotechnology (Chemistry)
Classification: CPC C | IPC C

Claim 9:
10. The antibody of claim 1, wherein
(A) the antibody that binds to CD8 is a multispecific CD8 antibody, wherein the multispecific CD8 antibody comprises:
(a) a first binding domain that binds CD8, and a second binding domain that binds to a second target,
wherein optionally
(i) the second target is CD4,
(ii) the second target is a T cell receptor (TCR) complex or
(iii) the second target is a T cell costimulatory molecule

(b) a first binding domain that binds CD8, a second binding domain that binds to a second target, and a third binding domain that binds to a third target,
wherein optionally
(i) the second target is CD4,
(ii) the second target is a TCR complex
(iii) the second target is a T cell costimulatory molecule
(iv) the second target is CD4, and
the third target is a TCR complex,

(v) the second target is CD4, and
the third target is a T cell costimulatory molecule or

(vi) the second target is a TCR complex and
the third target is a T cell costimulatory molecule or

(c) a first binding domain that binds CD8, and a second binding domain that binds to a second target, a third binding domain that binds to a third target, and a fourth binding domain that binds to a fourth target,
wherein optionally
(i) the second target is CD4,
(ii) the second target is a TCR complex or
(iii) the second target is a T cell costimulatory molecule
(iv) the second target is CD4, and
the third target is a TCR complex

(v) the second target is CD4,
and the third target is a T cell costimulatory molecule

(vi) the second target is a TCR complex and
the third target is a T cell costimulatory molecule or

(vii) the second target is CD4,
the third target is a TCR complex and
the fourth target is a T cell costimulatory molecule

(B) the antibody that binds to CD4 is a multispecific CD4 antibody, wherein the multispecific CD4 antibody comprises:
(a) a first binding domain that binds CD4, and a second binding domain that binds to a second target,
wherein optionally
(i) the second target is CD8,
(ii) the second target is a T cell receptor (TCR) complex or
(iii) the second target is a T cell costimulatory molecule

(b) a first binding domain that binds CD4, a second binding domain that binds to a second target, and a third binding domain that binds to a third target,
wherein optionally
(i) the second target is CD8,
(ii) the second target is a TCR complex
(iii) the second target is a T cell costimulatory molecule
(iv) the second target is CD8, and
the third target is a TCR complex

(v) the second target is CD8,
and the third target is a T cell costimulatory molecule

(vi) the second target is a TCR complex and
the third target is a T cell costimulatory molecule or

(c) a first binding domain that binds CD4, and a second binding domain that binds to a second target, a third binding domain that binds to a third target, and a fourth binding domain that binds to a fourth target,
wherein optionally
(i) the second target is CD8,
(ii) the second target is a TCR complex or
(iii) the second target is a T cell costimulatory molecule
(iv) the second target is CD8, and
the third target is a TCR complex

(v) the second target is CD8,
and the third target is a T cell costimulatory molecule

(vi) the second target is a TCR complex and
the third target is a T cell costimulatory molecule or

(vii) the second target is CD8,
the third target is a TCR complex-and
the fourth target is a T cell costimulatory molecule-or

(C) the multispecific antibody that binds to CD8 and CD4, comprises:
(a) a first binding domain that binds CD8, and a second binding domain that binds to CD4, and a third binding domain that binds to a third target;
wherein optionally
(i) the third target is a TCR complex or
(ii) the third target is a T cell costimulatory molecule or

(b) a first binding domain that binds CD8, and a second binding domain that binds to CD4, a third binding domain that binds to a third target, and a fourth binding domain that binds to a fourth target,
wherein optionally
the third target is a TCR complex and
the fourth target is a T cell costimulatory molecule.